What should a GLP-1 weight loss clinic track between visits?
Last updated
Track whether patients stay on therapy, not just the scale. In a 2024 study of 3,389 real-world patients, people with steady medication coverage lost about twice as much weight at one year as those with long gaps. Side effects, missed refills, eating habits, and strength are the early signals worth watching between visits.
What does this mean for your clinic?
The trial numbers are the ceiling, not the average. In the STEP 1 trial, adults on weekly semaglutide plus a lifestyle program lost 14.9 percent of body weight over 68 weeks, compared with 2.4 percent on placebo. In everyday care, the Cleveland Clinic data show a far smaller average. The gap between those two numbers is mostly what happens between visits.
How many patients stop, and when? A lot, and early. A 2024 study by Do and colleagues followed 195,915 new GLP-1 users through pharmacy claims. Among patients with obesity and no diabetes, 35.8 percent had stopped by 3 months and 50.3 percent by 12 months. New stomach and bowel side effects, higher out-of-pocket cost, and living in an area with high social needs were all tied to higher odds of stopping. Those are things a clinic can see coming if it is looking.
Why does stopping matter so much? Because the weight tends to come back. In the STEP 1 extension, 327 participants were followed for a year after semaglutide and the lifestyle program ended. They regained about two thirds of the weight they had lost, and most heart and metabolic gains drifted back toward baseline. The authors concluded that obesity is chronic and needs ongoing care. A patient who quietly drops off between visits is not a neutral event.
What else belongs on the list? Side effects come first. In STEP 1, nausea and diarrhea were the most common problems. They were usually mild and faded over time, but 4.5 percent of the semaglutide group stopped because of them. In the tirzepatide trial SURMOUNT-1, stomach side effects clustered in the step-up period, the first weeks of treatment when the medicine is slowly increased. That step-up window is when a quick check-in matters most.
A 2025 joint advisory from four obesity and nutrition societies adds the rest. It names side effects, nutrient gaps from eating less, muscle and bone loss, and low long-term adherence with weight regain as the main challenges. It recommends screening eating habits, emotional triggers, and disordered eating at the start. It also recommends checking strength and body composition, and supporting protein intake and resistance training during treatment. Digital tools and dietitian support are named as practical ways to deliver this.
Put together, the between-visit picture has five parts. Weight trend. Side effects, especially in the step-up weeks. Refills and missed injections. Eating, mood, and emotional triggers. Strength and activity. Any one of these can slip quietly between monthly visits. Two limits are worth stating. The Cleveland Clinic study is observational, and much of it covers older medicines and diabetes care, so newer agents may do better. And the trials were funded by the companies that make the drugs.
The takeaway
- Track persistence as a core outcome. A refill gap or a skipped week is an early warning, not a billing detail.
- Check in more often during the step-up weeks, when stomach side effects are most common and most patients decide whether to stay on.
- Pair the weight trend with eating habits, mood, and strength, so you see muscle loss or emotional eating before the next visit.
This is the work Asendar™ was built for: the weeks between visits, when a patient decides whether to stay on track. Auto-assigned check-ins and wearable data from Apple Health, Google Health, and Oura keep your team's picture current, and you can ask the brain button about any patient instead of hunting through old notes.
Start a 15-day free trial for your clinicTrack CoCM minutes, catch patients at risk of missing the code, export a billing packet. No card to start, $199/mo after the trial.